-
Mashup Score: 9Labcorp to acquire Invitae’s assets for $239M - 2 day(s) ago
William Blair analyst Andrew Brackmann said Labcorp is being aggressive in its M&A strategy, after announcing last month it would buy several of Bioreference Health’s testing businesses.
Source: www.medtechdive.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5ODAC Approves MRD End Point in Multiple Myeloma Trials - 6 day(s) ago
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Source: www.cancernetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 14
Kinnear et al. demonstrate the ability of myosin inhibitors to restore function in pediatric hypertrophic cardiomyopathy patient and gene-edited iPSC-cardiomyocytes harboring myosin variants. From monogenic to digenic to biallelic variants, these inhibitors outperform non-targeted drugs, signaling a promising path for myosin-targeted therapies and an urgent call for clinical trials in children.
Source: www.cell.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 14South Waterfront Ronald McDonald House at the OHSU Rood Family Pavilion · 3410 S Bond Ave, Portland, OR 97239 - 8 day(s) ago
★★★★★ · Non-profit organization
Source: www.google.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5ODAC Approves MRD End Point in Multiple Myeloma Trials - 11 day(s) ago
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Source: www.cancernetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5ODAC Approves MRD End Point in Multiple Myeloma Trials - 15 day(s) ago
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Source: www.cancernetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 24
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on…
Source: www.globenewswire.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 64Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM - Full Text View - ClinicalTrials.gov - 1 month(s) ago
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM – Full Text View.
Source: classic.clinicaltrials.govCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 9
TN-201 gene therapy is being studied in the Phase 1b MyPeak-1™ clinical trial for the treatment of genetic hypertrophic cardiomyopathy caused by variations i…
Source: www.youtube.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 11Alzheimer’s Disease: Developing Drugs for Treatment Guidance - 2 month(s) ago
Clincal / Medical
Source: www.fda.govCategories: General Medicine News, CardiologistsTweet
Some news in the land of #genes Labcorp acquires Invitae #CardioTwitter https://t.co/9jeNhuTlb1.